All AbMole products are for research use only, cannot be used for human consumption.
AV-951 (Tivozanib) is a potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM respectively.AV-951 (Tivozanib) blocks the proliferation and migration of endothelial cells in vitro, and suppresses angiogenesis and growth of human tumor xenografts in vivo.
| Cell Experiment | |
|---|---|
| Cell lines | HUVECs cells line |
| Preparation method | Endothelial cell proliferation. HUVECs were seeded in M-199 (Invitrogen, Carlsbad, CA) containing 5% FBS in collagen-coated 96-well plates (BD Biosciences, Bedford, MA) at a density of 4,000 cells/200 μL/well. After 24 hours, KRN951 was added followed by 20 ng/mL VEGF or 10 ng/mL bFGF, and the cells were cultured for 72 hours. [3H]thymidine (1 μCi/mL) was added and the cells were cultured for a further 12 hours. Cells were then harvested and their radioactivity was measured with a Liquid Scintillation Counter (Wallac 1205 Beta Plate; Perkin-Elmer Life Sciences, Boston, MA). |
| Concentrations | 0~1000nM |
| Incubation time | 72h |
| Animal Experiment | |
|---|---|
| Animal models | human tumor xenografts in athymic rats |
| Formulation | 0.5% methyl cellulose in distilled water |
| Dosages | 0.2 or 1 mg/kg for 14 days |
| Administration | oral gavage |
| Molecular Weight | 454.86 |
| Formula | C22H19ClN4O5 |
| CAS Number | 475108-18-0 |
| Solubility (25°C) | DMSO 18 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| Conbercept
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
| SU5208
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2). |
| VEGFR-IN-1
VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
| (Z)-Orantinib
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. |
| (Rac)-SAR131675
(Rac)-SAR131675 is the racemate of SAR131675. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
